Drug recalls, 2026-W14

FDA drug recalls, March 30 to April 5, 2026

FDA posted 7 drug recalls the week of March 30, 2026: 6 Class II and 1 Class III. Teva Pharmaceuticals USA, Inc has the most, with 3.

License: openFDA publishes this file under CC0 1.0.

FDA sorts recalls by risk. Class I: using the product could cause serious health problems or death. Class II: it could cause temporary or reversible health problems. Class III: it is unlikely to cause health problems.

For pharmacies and practices

Get this every Monday

Rivvi pulls the FDA drug recalls posted in the last 7 days and sends you the list each Monday morning. Add the drugs you stock or prescribe and it flags any that match.

Watch recalls in Rivvi

Free to start. Opens Rivvi, the AI workspace for healthcare teams, with the weekly watch turned on.

Recalls posted March 30 to April 5, 2026

Class II · Posted April 1, 2026 · Started March 17, 2026 · Ongoing

octreotide acetate

Product
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9262-08.
Firm
Teva Pharmaceuticals USA, Inc, Parsippany, NJ
Reason
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Lots
Lot:4400401, Exp.: 6/30/2026; 4401393, 4401494, 4401604, Exp.: 9/31/2026; 4500564, 4500601, 4500707, 4500796, 4500859, 4500918, 4500919, 4501006, Exp.: 3/31/2027.
Quantity
21,930 Cartons
Distribution
Nationwide in the USA
RxNorm
octreotide acetate (RxCUI 898589, 898601, 898605)
Recall number
D-0406-2026

Class II · Posted April 1, 2026 · Started March 17, 2026 · Ongoing

octreotide acetate

Product
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9259-08.
Firm
Teva Pharmaceuticals USA, Inc, Parsippany, NJ
Reason
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Lots
Lot: 4401491, 4401600, 4401603, 4401629, Exp.: 9/31/2026; 4500594, 4500786, 4500920, 4501007, 4501462, Exp.: 3/31/2027.
Quantity
19,869 Cartons
Distribution
Nationwide in the USA
RxNorm
octreotide acetate (RxCUI 898589, 898601, 898605)
Recall number
D-0405-2026

Class II · Posted April 1, 2026 · Started March 17, 2026 · Ongoing

octreotide acetate

Product
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9257-08.
Firm
Teva Pharmaceuticals USA, Inc, Parsippany, NJ
Reason
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Lots
Lot: 4401619, Exp.: 09/30/2026; 4501005, 03/31/2027.
Quantity
1,897 Cartons
Distribution
Nationwide in the USA
RxNorm
octreotide acetate (RxCUI 898589, 898601, 898605)
Recall number
D-0404-2026

Class II · Posted April 1, 2026 · Started March 17, 2026 · Ongoing

poractant alfa

Product
CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
Firm
Chiesi USA, Inc., Cary, NC
Reason
Lack of Assurance of Sterility
Lots
Lot #: 1213748, Exp. Date 09/2026; 1215076, 1215077, Exp. Date 10/26.
Quantity
7,235 vials
Distribution
Nationwide within the United States
RxNorm
poractant alfa (RxCUI 259216, 261329)
Recall number
D-0402-2026

Class II · Posted April 1, 2026 · Started March 16, 2026 · Ongoing

meclizine hydrochloride

Product
Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio, 43217.
Firm
Amerisource Health Services LLC, Columbus, OH
Reason
Failed tablet specifications.
Lots
Lot #1024852; Exp 9/30/2026
Quantity
697 cartons
Distribution
U.S. Nationwide
RxNorm
meclizine hydrochloride (RxCUI 995624, 995666)
Recall number
D-0418-2026

Class II · Posted April 1, 2026 · Started February 26, 2026 · Ongoing

levothyroxine sodium

Product
Levothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Sarigam, Valsad, Guajarat, INDIA NDC 33342-401-44
Firm
MACLEODS PHARMA USA, INC, Princeton, NJ
Reason
Subpotent Drug
Lots
Lot 16240062A, exp date 3/2026
Quantity
1315 bottles
Distribution
Nationwide
RxNorm
levothyroxine sodium (RxCUI 892246, 892251, 892255, 966220, 966221, +7 more)
Recall number
D-0403-2026

Class III · Posted April 1, 2026 · Started February 19, 2026 · Ongoing

sodium iodide i-131

Product
Gelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, International Isotopes Inc., Idaho Falls, ID 83401. NDC: 69208-003-15; 69208-003-25; 69208-003-35
Firm
Radnostix, Idaho Falls, ID
Reason
Failed Tablet/Capsule Specifications
Lots
Lot, expiry: Lot 3666245, exp: 02/28/2026; Lot 4546213, exp: 02/28/2026 and Lot 4951280, exp 09/30/2027
Quantity
2,699 blister cartons
Distribution
Nationwide in the US, including Puerto Rico
RxNorm
sodium iodide i-131
Recall number
D-0401-2026

Source: openFDA drug enforcement reports, as of October 21, 2026. Publisher page

About this data

Each row is one FDA drug enforcement report: one product from one firm. A week here is Monday to Sunday, keyed on the date FDA listed the recall in its weekly Enforcement Report. The date the firm started the recall is shown on each row and is often weeks earlier.

Class I means use of the product could cause serious health problems or death. Class II means it could cause temporary or reversible health problems. Class III means it is unlikely to cause health problems. RxNorm names and RxCUIs come from openFDA's match of the product to its drug label. Compounded products often have no match.

This page lists public records. It is not medical advice. Check the FDA record before acting on a recall.

Source: openFDA drug enforcement reports, as of October 21, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing